An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.